Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Kungalv – page 24

476 clinical trials in Kungalv, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Kungalv at a glance
476
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

476 trials in Kungalv

Open in trial search

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Dyslipidaemia

Not recruiting

Study of RBD5044 in Adults with Mixed Dyslipidemia to Evaluate its Safety and Effectiveness

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:RBD5044 sodium
  • Sponsor:Ribocure Pharmaceuticals AB

Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Cardiac failure+1

Not recruiting

Study on Sodium Zirconium Cyclosilicate for Improving Heart Failure Treatment in Patients with High-Risk Hyperkalemia

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Vastra Gotalandsregionen

Hodgkin's disease

Not recruiting

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.